Mexican healthtech Preventix raised an undisclosed amount from Impact Ventures, marking Impact’s first investment in Latin America through its PSM Seed fund.
Preventix offers a non-invasive cervical cancer screening test that detects precancerous lesions with over 85% accuracy using protein biomarkers in blood.
Preventix will use the funds to scale its screening program and expand access to early detection across Latin America.
“When we started Preventix, we wanted to do things differently: we wanted to bring reliable, accessible, and dignified technology to thousands of women,” said Mercedes Gutiérrez Smith, founder and CEO of Preventix.
Founded in 2019, Preventix holds patents in 153 countries and aims to make its test a global standard in preventive health.
Read more on DFSUD.
